Building better biobetters: from fundamentals to industrial application

Detalhes bibliográficos
Autor(a) principal: Torres-Obreque, Karin M.
Data de Publicação: 2022
Outros Autores: Meneguetti, Giovanna P., Muso-Cachumba, Jorge J., Feitosa, Valker A., Santos, João H. P. M., Ventura, Sónia P. M., Rangel-Yagui, Carlota O.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10773/35522
Resumo: Biological drugs or biopharmaceuticals off patent open a large market for biosimilars and biobetters, follow-on biologics. Biobetters, in particular, are new drugs designed from existing ones with improved properties such as higher selectivity, stability, half-life and/or lower toxicity/immunogenicity. Glycosylation is one of the most used strategies to improve biological drugs, nonetheless bioconjugation is an additional alternative and refers to the covalent attachment of polymers to biological drugs. Extensive research on novel polymers is underway, nonetheless PEGylation is still the best alternative with the longest clinical track record. Innovative trends based on genetic engineering techniques such as fusion proteins and PASylation are also promising. In this review, all these alternatives wereexplored as well as current market trends, legislation and future perspectives.
id RCAP_e1a3e203f18fae7e3ebfdf1dff472c54
oai_identifier_str oai:ria.ua.pt:10773/35522
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Building better biobetters: from fundamentals to industrial applicationBiobetterBiodegradable polymerFusion proteinGlycoengineeringPEGylationProtein engineeringBiological drugs or biopharmaceuticals off patent open a large market for biosimilars and biobetters, follow-on biologics. Biobetters, in particular, are new drugs designed from existing ones with improved properties such as higher selectivity, stability, half-life and/or lower toxicity/immunogenicity. Glycosylation is one of the most used strategies to improve biological drugs, nonetheless bioconjugation is an additional alternative and refers to the covalent attachment of polymers to biological drugs. Extensive research on novel polymers is underway, nonetheless PEGylation is still the best alternative with the longest clinical track record. Innovative trends based on genetic engineering techniques such as fusion proteins and PASylation are also promising. In this review, all these alternatives wereexplored as well as current market trends, legislation and future perspectives.Elsevier2023-01-01T00:00:00Z2022-01-01T00:00:00Z2022-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10773/35522eng1359-644610.1016/j.drudis.2021.08.009Torres-Obreque, Karin M.Meneguetti, Giovanna P.Muso-Cachumba, Jorge J.Feitosa, Valker A.Santos, João H. P. M.Ventura, Sónia P. M.Rangel-Yagui, Carlota O.info:eu-repo/semantics/embargoedAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-02-22T12:08:17Zoai:ria.ua.pt:10773/35522Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:06:29.037834Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Building better biobetters: from fundamentals to industrial application
title Building better biobetters: from fundamentals to industrial application
spellingShingle Building better biobetters: from fundamentals to industrial application
Torres-Obreque, Karin M.
Biobetter
Biodegradable polymer
Fusion protein
Glycoengineering
PEGylation
Protein engineering
title_short Building better biobetters: from fundamentals to industrial application
title_full Building better biobetters: from fundamentals to industrial application
title_fullStr Building better biobetters: from fundamentals to industrial application
title_full_unstemmed Building better biobetters: from fundamentals to industrial application
title_sort Building better biobetters: from fundamentals to industrial application
author Torres-Obreque, Karin M.
author_facet Torres-Obreque, Karin M.
Meneguetti, Giovanna P.
Muso-Cachumba, Jorge J.
Feitosa, Valker A.
Santos, João H. P. M.
Ventura, Sónia P. M.
Rangel-Yagui, Carlota O.
author_role author
author2 Meneguetti, Giovanna P.
Muso-Cachumba, Jorge J.
Feitosa, Valker A.
Santos, João H. P. M.
Ventura, Sónia P. M.
Rangel-Yagui, Carlota O.
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Torres-Obreque, Karin M.
Meneguetti, Giovanna P.
Muso-Cachumba, Jorge J.
Feitosa, Valker A.
Santos, João H. P. M.
Ventura, Sónia P. M.
Rangel-Yagui, Carlota O.
dc.subject.por.fl_str_mv Biobetter
Biodegradable polymer
Fusion protein
Glycoengineering
PEGylation
Protein engineering
topic Biobetter
Biodegradable polymer
Fusion protein
Glycoengineering
PEGylation
Protein engineering
description Biological drugs or biopharmaceuticals off patent open a large market for biosimilars and biobetters, follow-on biologics. Biobetters, in particular, are new drugs designed from existing ones with improved properties such as higher selectivity, stability, half-life and/or lower toxicity/immunogenicity. Glycosylation is one of the most used strategies to improve biological drugs, nonetheless bioconjugation is an additional alternative and refers to the covalent attachment of polymers to biological drugs. Extensive research on novel polymers is underway, nonetheless PEGylation is still the best alternative with the longest clinical track record. Innovative trends based on genetic engineering techniques such as fusion proteins and PASylation are also promising. In this review, all these alternatives wereexplored as well as current market trends, legislation and future perspectives.
publishDate 2022
dc.date.none.fl_str_mv 2022-01-01T00:00:00Z
2022-01
2023-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10773/35522
url http://hdl.handle.net/10773/35522
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1359-6446
10.1016/j.drudis.2021.08.009
dc.rights.driver.fl_str_mv info:eu-repo/semantics/embargoedAccess
eu_rights_str_mv embargoedAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799137719894409216

Registros relacionados